REG - CVS Group plc - Block listing Interim Review

CVSAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nRSN7852Qa&default-theme=true

RNS Number : 7852Q  CVS Group plc  14 July 2025

14 July 2025

 

CVS Group plc

("CVS" or the "Company")

 

Block Listing Interim Review

CVS, the UK's listed veterinary group and a leading provider of veterinary
services, makes the following notification pursuant to Schedule Six of the AIM
Rules for Companies regarding its existing block listing arrangements.
References to securities are to the Company's ordinary shares of 0.2 pence
each ("Ordinary Shares").

 Name of the company:                                                              CVS Group plc

 Name of relevant scheme:                                                          1.    CVS Group SAYE Plan; and

                                                                                   2.    CVS Long Term Incentive Plan

 Period of return:                        From:                                    12 January 2025        To:                    12 July 2025
 Balance of unallotted securities under scheme(s) from previous return:            1.    337,965

                                                                                   2.    68,393
 Plus: The amount by which the block scheme(s) has been increased since the        1.    Nil
 date of the last return (if any increase has been applied for):

                                                                                   2.    Nil
 Less:  Number of securities issued / allotted under scheme(s) during period:      1.    Nil

                                                                                   2.    Nil
 Equals: Balance under scheme(s) not yet issued / allotted at end of period:       1.    337,965

                                                                                   2.    68,393
 Number and class of securities originally listed and the date of admission:       1.    350,000 Ordinary Shares admitted on 30 December 2021

                                                                                   2.    120,000 Ordinary Shares admitted on 15 May 2023

 

 

Contacts:

CVS Group plc
 
    via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

 

Peel Hunt LLP (Nominated Adviser & Broker)
                           +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

   Berenberg (Joint Broker)
                                                 +44
(0)20 3207 7800

Toby Flaux / Michael Burke / James Thompson / Milo Bonser

 

Camarco (Financial
PR)

Ginny
Pulbrook                                                                                                    +44
(0)7961 315 138

   Letaba Rimell

   Tilly Butcher

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRUAAURVRUBAAR